Zobrazeno 1 - 10
of 349
pro vyhledávání: '"Christopher T. Ritchlin"'
Autor:
Philip J. Mease, Joseph F. Merola, Yoshiya Tanaka, Laure Gossec, Iain B. McInnes, Christopher T. Ritchlin, Robert B. M. Landewé, Akihiko Asahina, Barbara Ink, Andrea Heinrichs, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Laura C. Coates
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 5, Pp 1363-1382 (2024)
Abstract Introduction Psoriatic arthritis (PsA) is a chronic inflammatory disease requiring long-term treatment. Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, has demonstrated tolerabili
Externí odkaz:
https://doaj.org/article/4bbb5fc59b154e17b4cb6d05b6603d8e
Autor:
Alexis Ogdie, Joseph F. Merola, Philip J. Mease, Christopher T. Ritchlin, Jose U. Scher, Kimberly Parnell Lafferty, Daphne Chan, Soumya D. Chakravarty, Wayne Langholff, Yanli Wang, Olivia Choi, Yevgeniy Krol, Alice B. Gottlieb
Publikováno v:
BMC Rheumatology, Vol 8, Iss 1, Pp 1-12 (2024)
Abstract Background Tumor necrosis factor inhibitors (TNFi) are frequently chosen as the first biologic for patients with psoriatic arthritis (PsA). Given that many patients with PsA are TNFi inadequate responders (TNF-IR; either inadequate efficacy
Externí odkaz:
https://doaj.org/article/8af8899c7fd64bf9a16ff7465d160dd3
Autor:
Stefan Siebert, Kristen M. Sweet, Christopher T. Ritchlin, Elizabeth C. Hsia, Alexa P. Kollmeier, Xie L. Xu, Loqmane Seridi, Qingxuan Song, Sheng Gao, Warner Chen, Michelle Miron
Publikováno v:
ACR Open Rheumatology, Vol 5, Iss 9, Pp 490-498 (2023)
Objective To evaluate gene expression in blood of patients with psoriatic arthritis (PsA) versus healthy controls and identify changes associated with guselkumab treatment. Methods Whole blood transcriptome profiling via paired‐end RNA sequencing w
Externí odkaz:
https://doaj.org/article/ee686f1b1c8d4522be8be3992db06eb5
Autor:
James G. Krueger, Kilian Eyerich, Vijay K. Kuchroo, Christopher T. Ritchlin, Maria T. Abreu, M. Merle Elloso, Anne Fourie, Steven Fakharzadeh, Jonathan P. Sherlock, Ya-Wen Yang, Daniel J. Cua, Iain B. McInnes
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Interleukin (IL)-23, an IL-12 cytokine family member, is a hierarchically dominant regulatory cytokine in a cluster of immune-mediated inflammatory diseases (IMIDs), including psoriasis, psoriatic arthritis, and inflammatory bowel disease. We review
Externí odkaz:
https://doaj.org/article/3fb972d7f9ef4534a189cd8ccc187a46
Autor:
Robert Landewé, Joseph F Merola, Laure Gossec, Frank Behrens, Ana-Maria Orbai, Philip J Mease, Iain B McInnes, Dafna D Gladman, Laura C Coates, Alice B Gottlieb, Vishvesh Shende, Jason Coarse, Christopher T Ritchlin, Richard B Warren, Akihiko Asahina, Barbara Ink, Rajan Bajracharya
Publikováno v:
RMD Open, Vol 10, Iss 1 (2024)
Objectives To assess 52-week safety and efficacy of bimekizumab in patients with active psoriatic arthritis (PsA) and prior inadequate response/intolerance to tumour necrosis factor inhibitors.Methods Patients completing the 16-week phase III double-
Externí odkaz:
https://doaj.org/article/8c6f7873019c4474b1623173fd071db0
Autor:
H Mark Kenney, Kiana L Chen, Lindsay Schnur, Jeffrey I Fox, Ronald W Wood, Lianping Xing, Christopher T Ritchlin, Homaira Rahimi, Edward M Schwarz, Hani A Awad
Publikováno v:
PLoS ONE, Vol 19, Iss 7, p e0305623 (2024)
BackgroundDevelopment of reliable disease activity biomarkers is critical for diagnostics, prognostics, and novel drug development. Although computed tomography (CT) is the gold-standard for quantification of bone erosions, there are no consensus app
Externí odkaz:
https://doaj.org/article/e5c2e52c752f405ea8310305a7bf736a
Autor:
Yue Peng, H. Mark Kenney, Karen L. de Mesy Bentley, Lianping Xing, Christopher T. Ritchlin, Edward M. Schwarz
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
ObjectiveInflammatory-erosive arthritis is exacerbated by dysfunction of joint-draining popliteal lymphatic vessels (PLVs). Synovial mast cells are known to be pro-inflammatory in rheumatoid arthritis (RA). In other settings they have anti-inflammato
Externí odkaz:
https://doaj.org/article/80288ec9980c44ea93b144bd10879db1
Autor:
Dennis McGonagle, Iain B. McInnes, Atul Deodhar, Georg Schett, May Shawi, Soumya D. Chakravarty, Alexa P. Kollmeier, Xie L. Xu, Shihong Sheng, Stephen Xu, Christopher T. Ritchlin, Proton Rahman, Phillip J. Mease
Publikováno v:
ACR Open Rheumatology, Vol 5, Iss 4, Pp 227-240 (2023)
Objective Previous analyses of pooled DISCOVER‐1 and DISCOVER‐2 data through Week 24 showed significantly higher rates of dactylitis resolution in patients treated with guselkumab compared with placebo. Here, we investigate associations between d
Externí odkaz:
https://doaj.org/article/b952304b10bc473db051a75aae6f707d
Autor:
Christopher T. Ritchlin, Atul Deodhar, Wolf‐Henning Boehncke, Enrique R. Soriano, Alexa P. Kollmeier, Xie L. Xu, Federico Zazzetti, May Shawi, Yusang Jiang, Shihong Sheng, Philip S. Helliwell
Publikováno v:
ACR Open Rheumatology, Vol 5, Iss 3, Pp 149-164 (2023)
Objective To evaluate efficacy and safety of the interleukin‐23p19‐subunit inhibitor, guselkumab, in DISCOVER‐1 patients with active psoriatic arthritis (PsA) by prior use of tumor necrosis factor inhibitor (TNFi). Methods The phase 3, randomiz
Externí odkaz:
https://doaj.org/article/e4930dc2832540c9ac8cbcbd84cd1cd7
Autor:
H. Mark Kenney, Ronald W. Wood, Gabriel Ramirez, Richard D. Bell, Kiana L. Chen, Lindsay Schnur, Homaira Rahimi, Benjamin D. Korman, Lianping Xing, Christopher T. Ritchlin, Edward M. Schwarz, Calvin L. Cole
Publikováno v:
Arthritis Research & Therapy, Vol 25, Iss 1, Pp 1-16 (2023)
Abstract Background Although treatment options and algorithms for rheumatoid arthritis (RA) have improved remarkably in recent decades, there continues to be no definitive cure or pharmacologic intervention with reliable long-term efficacy. For this
Externí odkaz:
https://doaj.org/article/19b87fe1e574417196fd3fe8ae9f637d